Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224339 · ClinicalTrials.gov registry record
New Technologies to Determine Carotid Plaque Vulnerability
A clinical trial of Atherosclerosis and Carotid Artery Plaque, sponsored by Mayo Clinic.
- Completed
- Registry status
- 216
- Enrollment target
- 1
- Study location
NCT02224339 is a study of Atherosclerosis and Carotid Artery Plaque that has completed, run by Mayo Clinic. The registered enrollment target is 216 participants, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02224339, a study of Atherosclerosis and Carotid Artery Plaque, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 216 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis: Identification of vulnerable atherosclerotic plaques (with or without neovascularization) using carotid CEUS is an independent predictor of MACE (over clinical risk factors, stress echo wall motion results, and carotid ultrasound two-dimensional speckle tracking strain indices). Primary Aims: 1. Evaluate the diagnostic role of carotid CEUS and two-dimensional speckle tracking strain imaging for detection of carotid plaque: * To determine the feasibility and safety of Carotid CEUS and Two-dimensional speckle tracking strain imaging SE . * To determine if carotid CEUS and two-dimensional speckle tracking strain imaging findings are associated with coronary angiographic results in those patients undergoing clinically indicated cardiac catheterization. * To determine the diagnostic accuracy of CEUS in identifying a vulnerable atherosclerotic plaque and neovascularization compared to carotid MRI, in a subset of patients. 2. Evaluate the prognostic role of carotid CEUS and two-dimensional speckle tracking strain imaging for prediction of MACE: * To determine if plaque identification (with or without neovascularization) on Carotid CEUS SE can improve the overall prediction of MACE over stress echo results alone * To determine if Carotid ultrasound two-dimensional speckle tracking strain indices can improve the overall prediction of MACE over stress echo results alone. * To determine if the detection of plaque neovascularization by Carotid CEUS is an independent predictor of MACE (over clinical risk factors, stress echo wall motion results, and carotid ultrasound two-dimensional speckle tracking strain indices).
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02224339
The ClinicalTrials.gov registry entry for NCT02224339 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (80% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT02224339 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02224339 about?
NCT02224339 is a clinical study titled "New Technologies to Determine Carotid Plaque Vulnerability". Hypothesis: Identification of vulnerable atherosclerotic plaques (with or without neovascularization) using carotid CEUS is an independent predictor of MACE (over clinical risk factors, stress echo wall motion results, and carotid ultrasound two-dimensional speckle tracking strain indices). Primary...
What is the current status of trial NCT02224339?
This trial is currently completed. The enrollment target is 216 participants. The study started on 2014-09. Estimated completion is 2019-01.
What conditions does trial NCT02224339 study?
This clinical trial studies the following conditions: Atherosclerosis, Carotid Artery Plaque.
Who is sponsoring clinical trial NCT02224339?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02224339 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
RECRUITING · NA
-
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.